Evaluation of compliance with allocated asparaginase
| . | E coli–asparaginase no. (%) of patients . | Erwinia-asparaginase no. (%) of patients . |
|---|---|---|
| During IA | 354 (100) | 346 (100) |
| Patients received all planned doses | 287 (81) | 303 (88) |
| Patients switched to other asparaginase3-150 | 39 (11) | 24 (7) |
| During IIA | 300 (100) | 277 (100) |
| Patients received all planned doses | 198 (66) | 190 (69) |
| Patients switched to other asparaginase3-150 | 86 (29) | 80 (29) |
| . | E coli–asparaginase no. (%) of patients . | Erwinia-asparaginase no. (%) of patients . |
|---|---|---|
| During IA | 354 (100) | 346 (100) |
| Patients received all planned doses | 287 (81) | 303 (88) |
| Patients switched to other asparaginase3-150 | 39 (11) | 24 (7) |
| During IIA | 300 (100) | 277 (100) |
| Patients received all planned doses | 198 (66) | 190 (69) |
| Patients switched to other asparaginase3-150 | 86 (29) | 80 (29) |
Switch denotes a patient who received at least one injection of asparaginase he was not randomized to receive. Some patients did not receive all planned doses but were not switched to the other asparaginase.